Topline results from the lowest-dose MAD cohort in PepGen's Phase II FREEDOM2 study showed favorable safety and positive splicing and vHOT biomarker signals. Data are early and from the lowest dose, but the favorable safety and target-engagement readouts are likely to be viewed positively for the program's risk profile while awaiting higher-dose cohorts and full efficacy readouts.
Topline results from the lowest-dose MAD cohort in PepGen's Phase II FREEDOM2 study showed favorable safety and positive splicing and vHOT biomarker signals. Data are early and from the lowest dose, but the favorable safety and target-engagement readouts are likely to be viewed positively for the program's risk profile while awaiting higher-dose cohorts and full efficacy readouts.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
